Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 1

Status

Terminated 2Unknown 1Recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 218Thoracic 73Head & Neck 26Gynecologic 14Other solid neoplasm 13Lymphoid 10Breast 9Tumor-Agnostic 7CNS 6Sarcoma 4Genitourinary 4Endocrine 3Other neoplasm 2NET 2Dermatologic 2Myeloid 1

Conditions

Sarcoma 2Osteosarcoma 1Hemangiosarcoma 1Adenocarcinoma of Lung 1

Interventions

Radiotherapy 220Doxorubicin 210Cyclophosphamide 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 80Irinotecan 79pembrolizumab 75Radiation 69Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Peripheral Blood Stem Cell Transplantation 57Surgical Procedures, Operative 56Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
sintilimab × Sarcoma × Clear all
NCT05026736 2025-08-17

Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study

M.D. Anderson Cancer Center

Phase 2 Terminated
6 enrolled
Sarcoma

Hemangiosarcoma

NCT04589754 2024-01-02

Adriamycin and Ifosfamide Combined With Sintilimab

Sun Yat-sen University

Phase 2 Recruiting
176 enrolled
Sarcoma

Sarcoma

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1 Terminated
9 enrolled
SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT04356872 2020-07-14

The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Fudan University

Phase 2 Unknown
45 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡